Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Vaccitech price target lowered to $20 from $22 at H.C. Wainwright » 09:27
08/11/22
08/11
09:27
08/11/22
09:27
VACC

Vaccitech

$4.91 /

-0.08 (-1.60%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Yi Chen lowered the firm's price target on Vaccitech to $20 from $22 and keeps a Buy rating on the shares after the company reported its Q2 results earlier this week. The company's strong cash position should support operations through multiple catalysts over the next 12-18 months, said Chen, who now estimates a market value of the company of $760M.

ShowHide Related Items >><<
VACC Vaccitech
$4.91 /

-0.08 (-1.60%)

VACC Vaccitech
$4.91 /

-0.08 (-1.60%)

05/12/22 H.C. Wainwright
Vaccitech price target lowered to $22 from $23 at H.C. Wainwright
VACC Vaccitech
$4.91 /

-0.08 (-1.60%)

VACC Vaccitech
$4.91 /

-0.08 (-1.60%)

Tuesday
Syndicate
Vaccitech files $200M mixed securities shelf  17:33
08/09/22
08/09
17:33
08/09/22
17:33
VACC

Vaccitech

$4.99 /

+0.24 (+5.05%)

 
ShowHide Related Items >><<
VACC Vaccitech
$4.99 /

+0.24 (+5.05%)

VACC Vaccitech
$4.99 /

+0.24 (+5.05%)

05/12/22 H.C. Wainwright
Vaccitech price target lowered to $22 from $23 at H.C. Wainwright
VACC Vaccitech
$4.99 /

+0.24 (+5.05%)

VACC Vaccitech
$4.99 /

+0.24 (+5.05%)

Over a month ago
Conference/Events
Vaccitech management to meet virtually with William Blair » 04:55
06/27/22
06/27
04:55
06/27/22
04:55
VACC

Vaccitech

$5.89 /

-0.155 (-2.57%)

Virtual Meeting to be…

Virtual Meeting to be held on June 27 hosted by William Blair.

ShowHide Related Items >><<
VACC Vaccitech
$5.89 /

-0.155 (-2.57%)

VACC Vaccitech
$5.89 /

-0.155 (-2.57%)

05/12/22 H.C. Wainwright
Vaccitech price target lowered to $22 from $23 at H.C. Wainwright
VACC Vaccitech
$5.89 /

-0.155 (-2.57%)

VACC Vaccitech
$5.89 /

-0.155 (-2.57%)

Syndicate
Vaccitech files to sell 2.16M ordinary shares for holders  12:23
06/22/22
06/22
12:23
06/22/22
12:23
VACC

Vaccitech

$4.68 /

-0.1 (-2.09%)

 
ShowHide Related Items >><<
VACC Vaccitech
$4.68 /

-0.1 (-2.09%)

VACC Vaccitech
$4.68 /

-0.1 (-2.09%)

05/12/22 H.C. Wainwright
Vaccitech price target lowered to $22 from $23 at H.C. Wainwright
VACC Vaccitech
$4.68 /

-0.1 (-2.09%)

VACC Vaccitech
$4.68 /

-0.1 (-2.09%)

Hot Stocks
Vaccitech's VTP-300 shows efficacy in hepatitis B study » 06:05
06/22/22
06/22
06:05
06/22/22
06:05
VACC

Vaccitech

$4.78 /

+0.14 (+3.02%)

Vaccitech updated the…

Vaccitech updated the interim analysis of safety and efficacy data from the HBV002 study being presented as a poster at the 2022 EASL International Liver Congress. The updated analysis, which now includes 39 patients with at least three months of follow-up, shows that VTP-300 as a monotherapy or in combination with a single low-dose nivolumab at the time of the booster dose was safely administered with no treatment-related serious adverse events and two patients with mild, rapidly resolving transaminitis. In the VTP-300 monotherapy group, meaningful and durable reductions of Hepatitis B surface antigen, or HBsAg, were seen in all three patients with baseline HBsAg under 50 IU/mL. These dramatic declines have persisted in all three patients at their latest follow-up at five or eight months after the last dose of VTP-300. For the first eight patients who received VTP-300 in combination with a single low-dose of nivolumab at the time of the booster dose, the mean reduction in HBsAg was over 1 log10 at six months, an effect that persisted. A robust T cell response against all encoded antigens was observed following VTP-300 administration. Enrollment in the HBV002 study is complete with 55 patients enrolled. An updated interim analysis for all patients at the six month follow-up timepoint is expected at the end of 2022. A trial to look at timing of low dose nivolumab and additional doses of the MVA boost component of VTP-300 is planned in multiple countries, with the first patient expected to be dosed in Q3.

ShowHide Related Items >><<
VACC Vaccitech
$4.78 /

+0.14 (+3.02%)

VACC Vaccitech
$4.78 /

+0.14 (+3.02%)

05/12/22 H.C. Wainwright
Vaccitech price target lowered to $22 from $23 at H.C. Wainwright
VACC Vaccitech
$4.78 /

+0.14 (+3.02%)

VACC Vaccitech
$4.78 /

+0.14 (+3.02%)

Conference/Events
Vaccitech management to meet virtually with William Blair » 14:02
06/17/22
06/17
14:02
06/17/22
14:02
VACC

Vaccitech

$4.59 /

+0.32 (+7.49%)

Virtual Meeting to be…

Virtual Meeting to be held on June 27 hosted by William Blair.

ShowHide Related Items >><<
VACC Vaccitech
$4.59 /

+0.32 (+7.49%)

VACC Vaccitech
$4.59 /

+0.32 (+7.49%)

05/12/22 H.C. Wainwright
Vaccitech price target lowered to $22 from $23 at H.C. Wainwright
VACC Vaccitech
$4.59 /

+0.32 (+7.49%)

VACC Vaccitech
$4.59 /

+0.32 (+7.49%)

Hot Stocks
Arbutus, Vaccitech dose first patient in Phase 2a trial of AB-729 with VTP-300 » 07:39
06/06/22
06/06
07:39
06/06/22
07:39
ABUS

Arbutus Biopharma

$2.70 /

+0.05 (+1.89%)

, VACC

Vaccitech

$4.17 /

-0.22 (-5.01%)

Arbutus Biopharma…

Arbutus Biopharma Corporation (ABUS) and Vaccitech (VACC) announced the first patient dosed in a Phase 2a clinical trial. This trial will evaluate Arbutus' RNAi therapeutic candidate, AB-729, in combination with Vaccitech's T-cell stimulating immunotherapeutic, VTP-300, and standard-of-care nucleos(t)ide reverse transcriptase inhibitor therapy for the treatment of patients with virologically-suppressed chronic HBV infection. The randomized, multi-center, blinded, Phase 2a clinical trial will evaluate the safety, antiviral activity and immunogenicity of VTP-300 administered after AB-729 in virologically-suppressed cHBV patients. The trial is designed to enroll 40 cHBV patients. All patients will receive AB-729 plus NA therapy for 24 weeks. At week 24, treatment with AB-729 will stop. Patients will continue only their NA therapy and will be randomized to receive either VTP-300 or placebo for an additional 24 weeks. At week 48 all participants will be evaluated for eligibility to either discontinue or remain on NA therapy.

ShowHide Related Items >><<
VACC Vaccitech
$4.17 /

-0.22 (-5.01%)

ABUS Arbutus Biopharma
$2.70 /

+0.05 (+1.89%)

ABUS Arbutus Biopharma
$2.70 /

+0.05 (+1.89%)

03/14/22 H.C. Wainwright
Arbutus Biopharma price target raised to $8.50 from $8 at H.C. Wainwright
03/04/22 Chardan
Arbutus Biopharma price target raised to $6 from $5.50 at Chardan
12/29/21 Jefferies
Arbutus Biopharma assumed with a Hold at Jefferies
12/13/21 H.C. Wainwright
H.C. Wainwright sees Arbutus' $300M-plus licensing deal for AB-729 as low-risk
VACC Vaccitech
$4.17 /

-0.22 (-5.01%)

05/12/22 H.C. Wainwright
Vaccitech price target lowered to $22 from $23 at H.C. Wainwright
VACC Vaccitech
$4.17 /

-0.22 (-5.01%)

ABUS Arbutus Biopharma
$2.70 /

+0.05 (+1.89%)

VACC Vaccitech
$4.17 /

-0.22 (-5.01%)

ABUS Arbutus Biopharma
$2.70 /

+0.05 (+1.89%)

ABUS Arbutus Biopharma
$2.70 /

+0.05 (+1.89%)

Over a quarter ago
Recommendations
Vaccitech price target lowered to $22 from $23 at H.C. Wainwright » 11:50
05/12/22
05/12
11:50
05/12/22
11:50
VACC

Vaccitech

$3.88 /

+0.28 (+7.78%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Yi Chen lowered the firm's price target on Vaccitech to $22 from $23 and keeps a Buy rating on the shares post the Q1 results. The analyst says the company's "rich pipeline should provide multiple potential value inflection points going forward."

ShowHide Related Items >><<
VACC Vaccitech
$3.88 /

+0.28 (+7.78%)

VACC Vaccitech
$3.88 /

+0.28 (+7.78%)

05/25/21 William Blair
Vaccitech initiated with an Outperform at William Blair
05/25/21 Morgan Stanley
Vaccitech initiated with an Overweight at Morgan Stanley
05/25/21 Jefferies
Vaccitech initiated with a Buy at Jefferies
05/24/21 H.C. Wainwright
Vaccitech initiated with a Buy at H.C. Wainwright
VACC Vaccitech
$3.88 /

+0.28 (+7.78%)

VACC Vaccitech
$3.88 /

+0.28 (+7.78%)

Earnings
Vaccitech reports Q1 EPS 7c, consensus (31c) » 16:34
05/11/22
05/11
16:34
05/11/22
16:34
VACC

Vaccitech

$3.41 /

-1.09 (-24.22%)

Reports Q1 revenue $15M,…

Reports Q1 revenue $15M, consensus $3.57M. "We've already made solid progress across the Company this year and are excited to share our plans to advance our recently acquired SNAPvax platform into the clinic in multiple disease indications including HPV cancer and celiac disease," said Bill Enright, Vaccitech's CEO. "These are devastating diseases where we believe this novel platform provides a unique opportunity for potential cures. In addition, we expect to announce efficacy data in our chronic infectious disease programs in both HBV and HPV later this year. Finally, the royalty and milestone payments that we have begun to receive related to the sales of AstraZeneca's SARS CoV2 vaccine will contribute non-dilutive capital to these efforts."

ShowHide Related Items >><<
VACC Vaccitech
$3.41 /

-1.09 (-24.22%)

VACC Vaccitech
$3.41 /

-1.09 (-24.22%)

05/25/21 William Blair
Vaccitech initiated with an Outperform at William Blair
05/25/21 Morgan Stanley
Vaccitech initiated with an Overweight at Morgan Stanley
05/25/21 Jefferies
Vaccitech initiated with a Buy at Jefferies
05/24/21 H.C. Wainwright
Vaccitech initiated with a Buy at H.C. Wainwright
VACC Vaccitech
$3.41 /

-1.09 (-24.22%)

VACC Vaccitech
$3.41 /

-1.09 (-24.22%)

Periodicals
Vaccitech expects cash to fund operations into 2H24 » 07:17
03/25/22
03/25
07:17
03/25/22
07:17
VACC

Vaccitech

$5.26 /

-0.03 (-0.57%)

As of December 31, 2021,…

As of December 31, 2021, cash and cash equivalents were $214.1 million, compared to $43.3 million as of December 31, 2020. The increase was primarily due to completion of the Series B financing in the first quarter of 2021, which raised gross proceeds of $125.2 million, and to the initial public offering in the second quarter, which raised gross proceeds of $110.5 million. The Company believes its cash and cash equivalents are sufficient to fund operations into the second half of 2024.

ShowHide Related Items >><<
VACC Vaccitech
$5.26 /

-0.03 (-0.57%)

VACC Vaccitech
$5.26 /

-0.03 (-0.57%)

05/25/21 William Blair
Vaccitech initiated with an Outperform at William Blair
05/25/21 Morgan Stanley
Vaccitech initiated with an Overweight at Morgan Stanley
05/25/21 Jefferies
Vaccitech initiated with a Buy at Jefferies
05/24/21 H.C. Wainwright
Vaccitech initiated with a Buy at H.C. Wainwright
VACC Vaccitech
$5.26 /

-0.03 (-0.57%)

  • 30
    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.